Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mozart's sonata may tame seizures in children

NCT ID NCT05545540

Symptom relief Sponsor: University of Aberdeen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This study tests whether daily listening to Mozart's Sonata for two pianos in D major (K448) can reduce seizures and improve thinking skills in children with drug-resistant epilepsy. Researchers will compare a group that listens to K448 for 8 minutes each day for 2 months with a group that listens to control music. Parents will track seizures in a diary, and children will take cognitive tests before and after the music period to see if any changes occur.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Daily exposure to Mozart's Sonata for two pianos in D major (K448) or a control musical composition
What this could lead to
If daily listening to K448 reduces seizure frequency and improves cognitive function, it could offer a non-drug, low-risk add-on therapy for children with drug-resistant epilepsy.
What could go wrong
This is a small feasibility study, not a large trial, and the effect on seizures may be modest or absent. Listening to music is safe, but it is not a replacement for standard epilepsy treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 16 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children diagnosed with drug resistant epilepsy as per International League Against Epilepsy criteria: failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication (ASM) schedules to achieve sustained seizure freedom. Exclusion Criteria: * Children who undergo changes in ASM treatment during the study period. * Children with a seizure frequency of less than two episodes per month. * Children who underwent changes in ASM therapy less than one month before the study period. * Children included in other clinical intervention studies at the time of recruitment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cognitive disorder epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy Neurocognitive disorders

Contacts and locations

Locations

  • Royal Aberdeen Children's Hospital

    Aberdeen, AB25 2ZG, United Kingdom

  • Royal Hospital for Children & Young People

    Edinburgh, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.